DENVER, CO, August 3, 2005, GlobeImmune, Inc., a biopharmaceutical company that discovers and manufactures immunotherapy products known as Tarmogens™ to treat cancer and infectious disease, today announced the appointment of Francis V. Chisari, M.D. to its Scientific Advisory Board.
“We are pleased to welcome Dr. Chisari to our Scientific Advisory Board and look forward to his contributions to the clinical development of GlobeImmune’s products for viral infection,” said Dr. Timothy C. Rodell, CEO of GlobeImmune. Dr. Chisari joins existing advisors Teresa Brentnall, M.D., Paul Bunn, M.D., Edgar Engleman, M.D., Edward Mocarski, Ph.D., Robert (Chip) Schooley, M.D., Alan Venook, M.D., and Bruce Walker, M.D.
Dr. Chisari is currently Professor and Head of the Division of Experimental Pathology at the Scripps Research Institute. Dr. Chisari received his M.D. from Cornell University Medical College in 1968. He has been on the Scripps faculty since 1975 and has published over 325 papers in the area of hepatitis virus immunobiology and pathogenesis. Dr. Chisari sits on several advisory boards including the Distinguished Advisory Committee at the UCSD Cancer Center, the Scientific Advisory Board for the Center for the Study of HCV at Rockefeller University, the International Research Scholars Program at the Howard Hughes Medical Institute and various expert panels sponsored by the NIAID. In recognition of his scientific contributions, Dr. Chisari has received many honors and awards including election to fellowship in the American Association for the Advancement of Science and the American Academy of Microbiology, and membership in the Association of American Physicians, the National Academy of Sciences, and the Institute of Medicine.
About GlobeImmune, Inc.
GlobeImmune, Inc. is a biopharmaceutical company pioneering the discovery, development and manufacturing of potent, targeted molecular immunotherapies called Tarmogens for the treatment of cancer and infectious diseases. The Company’s lead product series, GI-4000 for the treatment of cancers of the lung and gastrointestinal tract, is currently in Phase 1 clinical trials. The Company initiated a Phase 1b trial for its second product, GI-5005, a Tarmogen for the treatment of chronic hepatitis C infection in July 2005.
Tarmogens are whole, heat-killed recombinant Saccharomyces cerevisiae yeast genetically modified to express one or more protein antigens that stimulate the immune system against diseased cells. Tarmogens are avidly taken up by the cells that activate the immune system called antigen presenting cells, to stimulate a T cell response against the desired target(s). GlobeImmune’s patented Tarmogen platform has a number of advantages over current approaches including that Tarmogens generate potent T cell immune responses, are not neutralized by the immune system, can be rapidly engineered and are simple to manufacture.
For additional information, please visit the company’s website at https://globeimmune.com/.